Omicron variant raises global concerns: Increased hospitalization and India's vaccination advantage

Azhagu Madhavan Sivalingam , Arjun Pandian
{"title":"Omicron variant raises global concerns: Increased hospitalization and India's vaccination advantage","authors":"Azhagu Madhavan Sivalingam ,&nbsp;Arjun Pandian","doi":"10.1016/j.ipha.2023.08.010","DOIUrl":null,"url":null,"abstract":"<div><p>The newly identified COVID-19 variant, B.1.1.529, initially detected in South Africa, was officially designated as the “Omicron” variant by the World Health Organization on November 26, 2021. This variant has raised concerns globally. From January 17 to November 26, 2021, Public Health Ontario (PHO) Library Services conducted extensive searches of published literature and preprints using the MEDLINE database. A total of six articles and one ongoing clinical trial were identified. Data from 15 published and unpublished reports, including interim findings, were collected. The WHO, ICMR, daily updates web page, internet sources, news, and hospitalization or death data were analyzed to assess the risk associated with the Omicron variant compared to non-hospitalized COVID-19 patients. The data suggested a potential 50% increase in the risk of hospitalization or death among Omicron patients compared to previous variants. Considering the emergence of the Omicron variant, it is important to note that India has an advantage due to its extensive immunization program, which annually vaccinates approximately 2.7 crorenewborns. However, it is crucial to ensure that vaccines meet all validation requirements and regulatory frameworks before they are made available to the public.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23000692/pdfft?md5=f2f7c96360f808908d1ca0045afa2c34&pid=1-s2.0-S2949866X23000692-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intelligent Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949866X23000692","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The newly identified COVID-19 variant, B.1.1.529, initially detected in South Africa, was officially designated as the “Omicron” variant by the World Health Organization on November 26, 2021. This variant has raised concerns globally. From January 17 to November 26, 2021, Public Health Ontario (PHO) Library Services conducted extensive searches of published literature and preprints using the MEDLINE database. A total of six articles and one ongoing clinical trial were identified. Data from 15 published and unpublished reports, including interim findings, were collected. The WHO, ICMR, daily updates web page, internet sources, news, and hospitalization or death data were analyzed to assess the risk associated with the Omicron variant compared to non-hospitalized COVID-19 patients. The data suggested a potential 50% increase in the risk of hospitalization or death among Omicron patients compared to previous variants. Considering the emergence of the Omicron variant, it is important to note that India has an advantage due to its extensive immunization program, which annually vaccinates approximately 2.7 crorenewborns. However, it is crucial to ensure that vaccines meet all validation requirements and regulatory frameworks before they are made available to the public.

欧米克隆变异引起全球关注:住院人数增加和印度疫苗接种优势
新发现的新冠病毒变种B.1.1.529最初在南非发现,于2021年11月26日被世界卫生组织正式指定为“欧米克隆”变种。这种变异引起了全球的关注。从2021年1月17日至11月26日,安大略省公共卫生部(PHO)图书馆服务使用MEDLINE数据库对已发表的文献和预印本进行了广泛的搜索。共有六篇文章和一项正在进行的临床试验被确定。收集了15份已发表和未发表报告的数据,包括中期调查结果。分析了世界卫生组织、ICMR、每日更新网页、互联网来源、新闻以及住院或死亡数据,以评估与非住院的COVID-19患者相比,与欧米克隆变异相关的风险。数据显示,与以前的变异相比,Omicron患者住院或死亡的风险可能增加50%。考虑到欧米克隆变异的出现,重要的是要注意到印度具有优势,因为其广泛的免疫计划,每年为大约2.7名转基因新生儿接种疫苗。然而,在向公众提供疫苗之前,确保疫苗符合所有验证要求和监管框架至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信